● Covered by 1 source · 1 reportMedium impact
Axiom Biosciences to List in Hong Kong Before U.S. by 2029
Axiom Biosciences plans to go public in Hong Kong in 2027, followed by a U.S. listing in 2029. This decision reflects the growing appeal of Hong Kong for biotech financing amid challenging fundraising environments in the U.S.
Key points
- Axiom will list in Hong Kong in 2027 and the U.S. in 2029.
- The move targets biotech-focused investors in Asia.
- Hong Kong has seen a notable rise in biotech listings.
Overview of Axiom Biosciences' Listing Plans
Axiom Biosciences, a San Diego-based biotech firm, is set to go public in Hong Kong in 2027. The firm plans a secondary listing in the U.S. in 2029, marking a strategic pivot for American biotechs traditionally favoring U.S. exchanges for listings.
Reasons for Choosing Hong Kong
The founder and CEO Remo Moomiaie-Qajar indicated that listing in Hong Kong will attract sophisticated investors specialized in biotechnology. The company views Hong Kong's stricter listing standards as indicative of a mature biotech ecosystem, which has performed well compared to similar firms listed on U.S. exchanges.
Market Dynamics and Challenges
Axiom cites a tougher fundraising environment in the U.S. for biotech firms, leading to an increased interest in alternative funding avenues. Rising costs of clinical trials and a declining pool of venture capitalists willing to invest have prompted this strategic change.
Hong Kong's Biotech Landscape
Hong Kong has become an increasingly attractive hub for biotech financing, with significant performance noted in the Hang Seng Biotech Index. The city has witnessed over 75% growth in this sector since January 2025, thanks to a supportive investment ecosystem and recent reforms that have simplified the IPO process.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Reporting from
Axiom Biosciences plans to go public in Hong Kong in 2027, followed by a U.S. listing in 2029. This decision reflects the growing appeal of Hong Kong for biotech financing amid challenging fundraising environments in the U.S.